Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are at least 18 years of age and not older than 78 with type 2 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Sitagliptin 100 mg oral tablets of sitagliptin once daily.
- Glipizide (Type: ACTIVE_COMPARATOR): Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.

Based on this trial design, predict the completion outcome and termination type (if applicable).